- Home
- BLCO vs GH Comparison
BLCO vs GH Comparison
Compare BLCO & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLCO
- GH
- Stock Information
- Founded
- BLCO 1853
- GH 2011
- Country
- BLCO Canada
- GH United States
- Employees
- BLCO N/A
- GH N/A
- Industry
- BLCO Ophthalmic Goods
- GH Medical Specialities
- Sector
- BLCO Health Care
- GH Health Care
- Exchange
- BLCO Nasdaq
- GH Nasdaq
- Market Cap
- BLCO 4.9B
- GH 4.9B
- IPO Year
- BLCO 2022
- GH 2018
- Fundamental
- Price
- BLCO $14.66
- GH $43.32
- Analyst Decision
- BLCO Hold
- GH Strong Buy
- Analyst Count
- BLCO 12
- GH 19
- Target Price
- BLCO $15.55
- GH $55.11
- AVG Volume (30 Days)
- BLCO 865.0K
- GH 1.8M
- Earning Date
- BLCO 07-30-2025
- GH 07-30-2025
- Dividend Yield
- BLCO N/A
- GH N/A
- EPS Growth
- BLCO N/A
- GH N/A
- EPS
- BLCO N/A
- GH N/A
- Revenue
- BLCO $4,829,000,000.00
- GH $773,996,000.00
- Revenue This Year
- BLCO $6.99
- GH $23.37
- Revenue Next Year
- BLCO $5.46
- GH $21.31
- P/E Ratio
- BLCO N/A
- GH N/A
- Revenue Growth
- BLCO 11.94
- GH 28.20
- 52 Week Low
- BLCO $10.45
- GH $20.14
- 52 Week High
- BLCO $21.69
- GH $53.42
- Technical
- Relative Strength Index (RSI)
- BLCO 68.51
- GH 30.22
- Support Level
- BLCO $13.81
- GH $44.61
- Resistance Level
- BLCO $14.49
- GH $46.62
- Average True Range (ATR)
- BLCO 0.42
- GH 1.60
- MACD
- BLCO 0.00
- GH -0.70
- Stochastic Oscillator
- BLCO 76.70
- GH 0.76
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.